Clinical Trials Logo

Renal Cancer clinical trials

View clinical trials related to Renal Cancer.

Filter by:

NCT ID: NCT00418496 Completed - Melanoma Clinical Trials

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Start date: November 8, 2006
Phase: Phase 1
Study type: Interventional

The primary objective of this study will be to determine the toxicity and Maximum Tolerated Dose (MTD) of the combination of high dose aldesleukin and sorafenib in previously untreated patients with metastatic or unresectable clear cell renal carcinoma (RCC) and metastatic melanoma.

NCT ID: NCT00399152 Completed - Renal Cancer Clinical Trials

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Start date: October 2006
Phase: Phase 1
Study type: Interventional

This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sunitinib malate will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of ensuring that they will be able to tolerate at least two courses of therapy, which would make them evaluable for response in a Phase II study.

NCT ID: NCT00398814 Completed - Tumors Clinical Trials

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

Start date: October 2006
Phase: Phase 1
Study type: Interventional

This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sorafenib will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of ensuring that they will be able to tolerate at least three courses of therapy, which would make them evaluable for response in a Phase II study.

NCT ID: NCT00381173 Completed - Breast Cancer Clinical Trials

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).

NCT ID: NCT00199888 Completed - Kidney Cancer Clinical Trials

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.

NCT ID: NCT00199875 Completed - Clinical trials for Renal Cell Carcinoma

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

Start date: July 6, 2005
Phase: Phase 1
Study type: Interventional

This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC). Study objectives were to determine the safety, targeting, and dosimetry of ^90Y-DOTA-cG250, using indium-111 conjugated chimeric G250 (^111In-DOTA-cG250) as a surrogate, as well as to evaluate the immunogenicity of cG250.